N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Sponsor: AbbVie • ClinicalTrials.gov ID: NCT07155174

Registry updated: 2026-10-13
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Interventions

  • ABBV-706 (Drug)
    Intravenous (IV) Infusion
  • Atezolizumab (Drug)
    IV Infusion
  • Etoposide (Drug)
    IV Infusion
  • Carboplatin (Drug)
    IV Injection
  • Carboplatin (Drug)
    IV Infusion
  • Lurbinectedin (Drug)
    IV Infusion

Eligibility criteria

Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy. * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment. * Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). * Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry. Exclusion Criteria: * Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC). * Known active/symptomatic central nervous system (CNS) metastases should be excluded. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded. * Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.

Conditions

Small Cell Lung Cancer

Locations

  • Yale University School of Medicine /ID# 278181 — New Haven, Connecticut, United States
  • University of Florida College of Medicine /ID# 277496 — Gainesville, Florida, United States
  • Ocala Oncology Center /ID# 278269 — Ocala, Florida, United States
  • Moffitt Cancer Center /ID# 277573 — Tampa, Florida, United States
  • Fort Wayne Medical Oncology And Hematology /ID# 277336 — Fort Wayne, Indiana, United States
  • Baptist Health Lexington /ID# 277729 — Lexington, Kentucky, United States
  • Dana-Farber Cancer Institute /ID# 277732 — Boston, Massachusetts, United States
  • Henry Ford Hospital - Detroit /ID# 277218 — Detroit, Michigan, United States
  • Missouri Cancer Associates /ID# 278299 — Columbia, Missouri, United States
  • University Hospitals Cleveland Medical Center /ID# 277556 — Cleveland, Ohio, United States
  • The University of Texas MD Anderson Cancer Center /ID# 277929 — Houston, Texas, United States
  • Virginia Cancer Specialists - Fairfax /ID# 278298 — Fairfax, Virginia, United States
  • Grand Hopital de Charleroi - Les Viviers /ID# 276897 — Charleroi, Hainaut, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 276781 — Hasselt, Limburg, Belgium
  • AZ Maria Middelares /ID# 277027 — Ghent, Oost-Vlaanderen, Belgium
  • Groupe Sante CHC - Clinique du MontLegia /ID# 276783 — Liège, Belgium
  • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 277167 — Beijing, Beijing Municipality, China
  • Henan Cancer Hospital /ID# 277059 — Zhengzhou, Henan, China
  • Union Hospital Tongji Medical College /ID# 277912 — Wuhan, Hubei, China
  • The First affiliated hospital of Nanchang University /ID# 277247 — Nanchang, Jiangxi, China
  • Shanghai East Hospital /ID# 277111 — Shanghai, Shanghai Municipality, China
  • Shanghai Pulmonary Hospital /ID# 276960 — Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University /ID# 277852 — Chengdu, Sichuan, China
  • Lungenfachklinik Immenhausen /ID# 278005 — Immenhausen, Hesse, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH /ID# 277466 — Marburg, Hesse, Germany
  • Evangelische Lungenklinik Berlin /ID# 277094 — Berlin, Germany
  • Meir Medical Center /ID# 277292 — Kefar Sava, Central District, Israel
  • Assuta Ashdod Medical Center /ID# 276661 — Ashdod, Southern District, Israel
  • The Chaim Sheba Medical Center /ID# 276660 — Ramat Gan, Tel Aviv, Israel
  • Rambam Health Care Campus- Haifa /ID# 276663 — Haifa, Israel
  • Hadassah Medical Center-Hebrew University /ID# 276662 — Jerusalem, Israel
  • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 276792 — Rome, Roma, Italy
  • Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 276789 — Orbassano, Torino, Italy
  • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 277744 — Roma, Italy
  • National Cancer Center Hospital East /ID# 277239 — Kashiwa-shi, Chiba, Japan
  • Shizuoka Cancer Center /ID# 277243 — Sunto-gun, Shizuoka, Japan
  • Tokyo Metropolitan Komagome Hospital /ID# 277335 — Bunkyo Ku, Tokyo, Japan
  • National Cancer Center Hospital /ID# 277237 — Chuo-Ku, Tokyo, Japan
  • Wakayama Medical University Hospital /ID# 277260 — Wakayama, Wakayama, Japan
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeyla /ID# 276907 — Poznan, Greater Poland Voivodeship, Poland
  • Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 276910 — Lublin, Lublin Voivodeship, Poland
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 277112 — Warsaw, Masovian Voivodeship, Poland
  • University Clinical Center Serbia /ID# 277007 — Belgrade, Beograd, Serbia
  • Clinical Hospital Center - Bezanijska Kosa /ID# 277013 — Belgrade, Beograd, Serbia
  • University Clinical Center Nis /ID# 277180 — Niš, Nisavski Okrug, Serbia
  • Institute For Pulmonary Diseases Of Vojvodina /ID# 277003 — Kamenitz, Sremski Okrug, Serbia
  • University Clinical Center Kragujevac /ID# 277179 — Kragujevac, Sumadijski Okrug, Serbia
  • National Cancer Center /ID# 277434 — Goyang-si, Gyeonggido, South Korea
  • Chungbuk National University Hospital /ID# 277429 — Cheongju-si, North Chungcheong, South Korea
  • Seoul National University Hospital /ID# 277271 — Seoul, Seoul Teugbyeolsi, South Korea
  • Yonsei University Health System - Severance Hospital /ID# 277597 — Seoul, Seoul Teugbyeolsi, South Korea
  • Asan Medical Center /ID# 277603 — Seoul, Seoul Teugbyeolsi, South Korea
  • Samsung Medical Center /ID# 277615 — Seoul, Seoul Teugbyeolsi, South Korea
  • Hospital Regional Universitario de Malaga /ID# 276927 — Málaga, Andalusia, Spain
  • Complejo Hospitalario Universitario A Coruna /ID# 276922 — A Coruña, Spain
  • Hospital Clinic de Barcelona /ID# 276878 — Barcelona, Spain
  • Hospital General Universitario Gregorio Maranon /ID# 276877 — Madrid, Spain
  • Hospital Universitario 12 de Octubre /ID# 277251 — Madrid, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267 — Kaohsiung City, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital /ID# 277725 — Kaohsiung City, Taiwan
  • Chung Shan Medical University Hospital /ID# 277660 — Taichung, Taiwan
  • Taipei Veterans General Hospital /ID# 277263 — Taipei, Taiwan
  • Linkou Chang Gung Memorial Hospital /ID# 277264 — Taoyuan City, Taiwan
  • Adana Sehir Hastanesi /ID# 277082 — Adana, Turkey (Türkiye)
  • Memorial Ankara Hastanesi /ID# 276840 — Ankara, Turkey (Türkiye)
  • Gazi University Medical Faculty /ID# 276843 — Ankara, Turkey (Türkiye)
  • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 277076 — Ankara, Turkey (Türkiye)
  • Liv Hospital Ankara /ID# 276842 — Ankara, Turkey (Türkiye)
  • Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 276839 — Istanbul, Turkey (Türkiye)
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record